

INFORMATION SHEET

AMS Guide to Equivalent MHT/HRT Doses New Zealand Only

This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different MHT/HRT products available in New Zealand in March 2017. HRT is now referred to as Menopausal Hormone Therapy (MHT). The intention of this sheet is to help physicians change their patients to higher or lower approximate doses of MHT if needing to tailor therapy, or remain within the same approximate dose if needing to change brands of MHT. Private/non Pharmac subsidised script products are marked with an *.

Oestrogen and progestogen combination MHT

Use cyclical oestrogen and progestogen combinations at peri-menopause or if less than 12 months amenorrhoea

Medium dose		
Trisequens*	tablet	1 and 2mg oestradiol/1mg norethisterone

Continuous oestrogen and progestogen combinations

Should be used if 12 months since LMP or after 12 months cyclical MHT

Low dose		
Product	Presentation	Composition
Kliovance*	tablet	1mg oestradiol/0.5mg norethistrone
Other Low dose hormonal options		
Livial*, Xyvion*	tablet	2.5mg tibolone
Duavive* (oestrogen/SERM combination)	tablet	0.45mg conjugated equine oestrogens / 20mg bazedoxifene
Medium dose		
Kliogest*	tablet	2mg oestradiol/1mg norethistrone
Premia 2.5 continuous*	tablet	0.625mg conjugated equine oestrogens/ 2.5mg medroxyprogesterone acetate
Premia 5 continuous* (same oestrogen, more progestogen than Premia 2.5 continuous)	tablet	0.625mg conjugated equine oestrogens/ 5mg medroxyprogesterone acetate
Estalis continuous* 50/140	transdermal patch	50mcg 17 B oestradiol/140mcg norethisterone acetate (twice weekly application)
Estalis continuous* 50/250 (same oestrogen, more progestogen than Estalis continuous 50/140)	transdermal patch	50mcg 17 B oestradiol/250mcg norethisterone acetate (twice weekly application)

Note: Medical and scientific information provided and endorsed by the Australasian Menopause Society might not be relevant to a particular person's circumstances and should always be discussed with that person's own healthcare provider. This Information Sheet may contain copyright or otherwise protected material. Reproduction of this Information Sheet by Australasian Menopause Society Members and other health professionals for clinical practice is permissible. Any other use of this information (hardcopy and electronic versions) must be agreed to and approved by the Australasian Menopause Society. ID:2017-05-16nz

Oestrogen only therapy: Only use these if patient has had a hysterectomy or in combination with a progestogen or Mirena if intact uterus

Low dose		
Product	Presentation	Composition
Estrofem*	tablet	1mg 17 B oestradiol
Progynova	tablet	1mg oestradiol valerate
Premarin*	tablet	0.3mg conjugated equine oestrogen
Estradot 25	transdermal patch	25 /24hrs 17B oestradiol (twice weekly application)
Medium dose		
Progynova	tablet	2mg oestradiol valerate
Estradot 50	transdermal patch	50mcg/24 hours 17B oestradiol (twice weekly application)
Premarin*	tablet	0.625mg conjugated equine oestrogens
Sandrena*	gel	1mg oestradiol (daily application)
High dose		
Estradot 75	transdermal patch	75 or 100mcg/24 hours (twice weekly application)
Estradot 100	patch	application)
Oestradiol implants - No longer available		
Oestrogen only vaginal therapy		
Product	Presentation	Composition
Ovestin	cream	1mg/g oestriol
Ovestin	pessary	0.5mg oestriol
Vagifem Low*	pessary	10mcg oestradiol

Progestogen

Suggested alternative doses for use with the oestrogen preparations above where fixed dose therapy is not suitable

Low dose for use with low dose oestrogen		
Product	Presentation	Composition
Provera (1/2 of 5mg tablet)	tablet	2.5mg medroxyprogesterone acetate
Provera 2.5mg tablet*	tablet	2.5mg medroxyprogesterone acetate
Primolut N (1/4 of 5mg tablet)	tablet	1.25 mg norethisterone
Utrogestan*	capsule	100 mg micronized progesterone
Mirena*	device (5 years)	20mcg/24hrs levonorgestrel
(Pharmac indication for menorrhagia/anaemia)		

Low dose progestogen-only contraceptive pills (Microlut (30mcg levonorgestrel), and Noriday (both 350mcg norethisterone) are used by some clinicians in various doses but there is limited data for dosages of these pills required for endometrial protection. 1 mg norethisterone was considered the minimum dose (cyclical or continuous) for adequate endometrial protection in the Cochrane Review (Cochrane Database Syst Rev. 2009 Apr 15;(2):CS000402).

Medium dose for use with medium dose oestrogen		
Product	Presentation	Dose
Primolut N (1/4 of 5mg tablet)	tablet	1.25 mg norethisterone
Provera	tablet	5mg medroxyprogesterone acetate
Utrogestan*	capsule	100 mg micronized progesterone
Mirena*	device (5 years)	20mcg/24hrs levonorgestrel
(Pharmac indication for menorrhagia/anaemia)		
Higher dose (for use in cyclical therapy or continuous therapy with high dose oestrogen)		
Primolut N (1/2 5mg tablet)	tablet	2.5mg norethisterone
Provera	tablet	10mg medroxyprogesterone acetate
Utrogestan*	capsule	200 mg micronized progesterone